What Is Psychedelic-Assisted Therapy? EEG and Neural Mechanisms
This guide is for educational and informational purposes only. Psychedelic substances are controlled substances in most jurisdictions. This article does not encourage, endorse, or provide guidance for the non-medical use of any psychedelic substance. Psychedelic-assisted therapy should only be pursued through legal clinical trials or authorized therapeutic programs under professional medical supervision. If you're interested in psychedelic therapy, consult a qualified healthcare provider about legal options in your area.
The Most Interesting Brain Data Nobody Expected
In the spring of 2012, a research team at Imperial College London published a study that confused nearly everyone who read it. Robin Carhart-Harris and David Nutt gave psilocybin (the active compound in magic mushrooms) to volunteers inside an fMRI scanner and measured what happened. The prevailing assumption was simple: a drug that produces intense visual hallucinations, emotional upheaval, and the feeling that the boundaries of the self have dissolved must be activating the brain like crazy. More activity. More firing. More everything.
The scans showed the opposite.
Psilocybin decreased brain activity. Specifically, it decreased activity in the brain's most densely connected hub regions, the areas that serve as the neural equivalent of major highway interchanges. The biggest decreases occurred in the default mode network (DMN), the system responsible for your sense of self, your autobiographical narrative, and the ceaseless internal monologue that tells you who you are and what everything means.
This finding didn't just surprise neuroscientists. It changed the entire framework for understanding how psychedelics work. And it opened a door to a question that's still reverberating through psychiatry: what if the conditions we call mental illness are, at their root, problems of a brain that's too rigidly organized? And what if psychedelics work precisely because they temporarily dismantle that rigidity?
A 50-Year Detour
Before we get into the neuroscience, it's worth understanding why we're only figuring this out now. Because we should have figured it out decades ago.
Between the 1950s and the mid-1960s, psychedelic research was one of the most active areas in psychiatry. LSD had been studied in over 1,000 clinical papers involving some 40,000 patients. The results for alcoholism were so promising that Bill Wilson, the co-founder of Alcoholics Anonymous, advocated for LSD therapy. Psilocybin was being studied at Harvard by Timothy Leary and Richard Alpert (later Ram Dass). The mood was electric. Researchers genuinely believed they were on the verge of understanding consciousness itself.
Then the cultural war on psychedelics shut everything down. LSD escaped the laboratory, became associated with the counterculture, and was classified as a Schedule I substance in 1970 under the Controlled Substances Act. Psilocybin, DMT, and mescaline followed. Research permits dried up almost overnight. For the next three decades, studying psychedelics in humans was effectively impossible.
The renaissance began around 2006, when Roland Griffiths at Johns Hopkins published a landmark paper demonstrating that psilocybin could occasion "mystical experiences" with lasting positive effects on well-being and personality openness. The paper was methodologically bulletproof. It reopened the door.
In the years since, the field has moved at astonishing speed. The FDA has granted breakthrough therapy designation to psilocybin for treatment-resistant depression and to MDMA for PTSD. Australia legalized therapeutic use of both substances in 2023. Phase 3 clinical trials are underway or completed at institutions including Johns Hopkins, NYU, Imperial College London, and the Usona Institute.
And with modern neuroimaging, particularly EEG, we can finally see what these substances do inside the brain with a level of detail that 1960s researchers couldn't have imagined.
What EEG Reveals: The Entropic Brain
The most important theoretical framework to emerge from psychedelic neuroscience comes from Robin Carhart-Harris, and it's called the Entropic Brain Hypothesis. Here's the core idea.
Your brain is a prediction machine. It builds models of the world and uses those models to interpret incoming information. Most of the time, this is incredibly useful. You don't need to figure out what a chair is every time you see one. Your brain recognizes the pattern instantly and moves on.
But these predictive models can become too rigid. When the brain's top-down predictions become so dominant that they override incoming sensory information and flexible thinking, you get pathological states. Depression is the brain rigidly predicting that nothing will improve. Anxiety is the brain rigidly predicting danger. Addiction is the brain rigidly routing all motivation through a single reward pathway. OCD is the brain rigidly predicting contamination or disaster.
Entropy, in information theory, measures the unpredictability of a signal. A completely predictable signal (like a metronome) has zero entropy. A completely random signal has maximum entropy. Normal waking consciousness sits somewhere in the middle: organized enough to function, flexible enough to adapt.
Here's what EEG shows during psychedelic experiences: entropy goes up. Significantly.
A series of studies from Imperial College London measured something called Lempel-Ziv complexity (a mathematical measure of signal entropy) in EEG recordings during psilocybin, LSD, and ketamine sessions. Every psychedelic they tested produced the same result: brain signals became measurably more complex, more unpredictable, and less dominated by the usual rhythmic patterns.
This increase in entropy correlates with the subjective experience of the psychedelic state. The degree of entropy increase on EEG predicts the intensity of reported changes in self-perception, visual experience, and boundary dissolution. More entropy equals more "trip."
| EEG Measure | Normal Waking State | Psychedelic State | What It Means |
|---|---|---|---|
| Alpha power (8-13 Hz) | Strong, especially in posterior regions | Significantly decreased | The brain's normal resting-state rhythm is disrupted, reflecting reduced top-down predictive processing |
| Lempel-Ziv complexity | Moderate (organized but flexible) | Increased beyond normal waking | Brain signals become more complex and less predictable than ordinary consciousness |
| Signal diversity (entropy) | Baseline | Increased across cortex | More information content per unit of brain activity, correlating with richer subjective experience |
| Default mode network coherence | High internal coherence | Dramatically reduced | The self-narrative network loses its usual coordinated activity |
| Gamma power (30-100 Hz) | Moderate | Increased in some regions | Possibly reflecting enhanced sensory processing and binding of novel perceptual content |
| Cross-frequency coupling | Organized hierarchical coupling | Disrupted | Normal relationships between fast and slow oscillations break down, flattening the brain's information hierarchy |
The Alpha Collapse: Watching the Brain's Editor Go Offline
Of all the EEG changes during psychedelic experiences, the collapse of alpha oscillations is perhaps the most telling.
alpha brainwaves, those smooth oscillations between 8 and 13 Hz, are the brain's dominant rhythm during restful wakefulness. For a long time, they were thought to reflect a kind of neural idling. But the current understanding is far more interesting. Alpha oscillations function as an inhibitory gating mechanism. They filter information. They determine what gets through to conscious awareness and what gets suppressed.
Think of alpha waves as your brain's editor. They select which neural signals are allowed into the final draft of your conscious experience and which ones get cut. This is why, in normal waking consciousness, you don't perceive every possible signal your brain could generate. Your alpha rhythm keeps the noise down and the signal clean.
Psychedelics turn the editor off.
When alpha power collapses, as it does dramatically under psilocybin and LSD, the filtering mechanism weakens. Signals that would normally be suppressed now reach conscious awareness. This explains several hallmark features of the psychedelic experience: synesthesia (when filtering between sensory modalities breaks down), vivid geometric hallucinations (when normally suppressed internal visual representations become conscious), and the feeling of significance that pervades the experience (when the normal filtering of salience signals becomes less discriminating).
On EEG, this alpha collapse is one of the strongest and replicable findings in psychedelic neuroscience. It's been demonstrated with psilocybin, LSD, DMT, and ayahuasca across multiple laboratories. And it correlates consistently with the intensity of the subjective effects.
The Default Mode Network: Where the Self Dissolves
The default mode network comes up a lot in these pages. It's the brain's self-referential system, the network that generates your sense of "me." Your autobiography. Your running narrative about who you are and what your life means.
In psychedelic states, the DMN doesn't just quiet down. Its internal coherence collapses. The regions that normally oscillate in tight synchrony lose their coordination. On EEG, this shows up as reduced coherence in the theta and alpha bands between midline frontal and parietal sites, the scalp locations that overlie DMN hubs.
This is what ego dissolution feels like from the inside: the story of "you" temporarily stops being told. Not because you lose consciousness. You're awake, you're aware, you're experiencing more intensely than usual. But the narrator is absent. The usual sense of being a separate self looking out at the world from behind your eyes dissolves into a more boundary-less kind of awareness.
This sounds mystical, and the experience is often described in mystical terms. But on an EEG trace, it's a measurable phenomenon. The oscillatory patterns that normally maintain the self-referential network are disrupted. The coherence drops. The entropy rises. And for the first time, the brain is freed from whatever narrative it's been locked into.
Why This Matters for Therapy
Here's the critical question: how does temporarily scrambling someone's brain help them heal?
The answer lies in what happens after the entropy spike. Psychedelics don't just increase disorder. They increase plasticity. The brain becomes temporarily more malleable, more capable of forming new connections and breaking old ones.
Research published in Neuron in 2018 by Ly and colleagues showed that psychedelics promote rapid growth of dendritic spines and synapses in cortical neurons. A single dose of psychedelic (DMT, LSD, psilocybin analogs) produced structural neuroplasticity comparable to what ketamine produces, and in some cases exceeded it. The neurons literally grew new branches and connection points.
On a systems level, this means that the rigid patterns maintaining a psychiatric condition, the rumination loops of depression, the fear circuits of PTSD, the compulsive reward pathways of addiction, become temporarily destabilized. And in that window of destabilization, with the right therapeutic support, new patterns can form.
This is why psychedelic-assisted therapy isn't just about the drug. The therapy is essential. The psychedelic opens the window. The therapy determines what happens while the window is open.
The Three-Phase Model
Modern psychedelic-assisted therapy follows a consistent three-phase structure:
Preparation (1 to 3 sessions before dosing). The patient builds a therapeutic relationship with their guides, discusses their history and intentions, and learns what to expect. This isn't just practical logistics. The preparation shapes the "set" (mindset), which profoundly influences the experience.
The dosing session (typically 6 to 8 hours). The patient takes the psychedelic in a comfortable, controlled environment with two trained therapists present. They usually lie down, wear eyeshades, and listen to a curated music playlist. The therapists provide support and reassurance but generally don't direct the experience. The patient's own psyche drives the content.
Integration (2 to 6 sessions after dosing). This is where the therapeutic work crystallizes. The patient processes the experience with their therapist, makes meaning of the insights that emerged, and translates them into concrete changes in thought patterns and behavior. Without integration, the insights from the psychedelic experience tend to fade. With it, they can produce lasting transformation.
The Evidence So Far
Let's look at what the clinical trials actually show.
Psilocybin for Depression
The flagship trial is the phase 2b study by COMPASS Pathways, published in The New England Journal of Medicine in 2022. Of 233 participants with treatment-resistant depression (meaning they'd failed at least two antidepressant medications), those who received a single 25mg dose of psilocybin with therapeutic support showed significantly greater improvement in depression scores at three weeks compared to those who received a 1mg control dose.
A Johns Hopkins trial published in JAMA Psychiatry in 2021 found that two doses of psilocybin with supportive therapy produced large, rapid, and sustained antidepressant effects. At one month, 71% of participants showed a clinically significant response, and 54% were in remission.
These are remarkable numbers for a treatment-resistant population, people who, by definition, had not responded to conventional treatment.
MDMA for PTSD
MDMA is not technically a classical psychedelic (it's an empathogen/entactogen), but its therapeutic mechanism shares key features with psychedelic-assisted therapy. The MAPS-sponsored phase 3 trial, published in Nature Medicine in 2023, showed that three MDMA-assisted therapy sessions produced dramatic improvements. Approximately 71% of participants no longer met diagnostic criteria for PTSD, compared to 48% in the therapy-with-placebo group.
On EEG, MDMA produces a distinctive pattern: reduced amygdala reactivity, increased frontolimbic connectivity, and enhanced theta oscillations associated with memory reconsolidation. The drug appears to create a state where traumatic memories can be accessed without triggering the usual overwhelming fear response, allowing the therapeutic relationship and the patient's own psychological resources to process what was previously unprocessable.
Psilocybin for End-of-Life Anxiety
Two landmark studies, one from Johns Hopkins and one from NYU, both published in the Journal of Psychopharmacology in 2016, showed that a single psilocybin session produced immediate and sustained reductions in anxiety and depression in patients with life-threatening cancer diagnoses. At six months, approximately 80% of participants continued to show clinically significant reductions in distress.
These studies reported that the intensity of the "mystical experience" (measured by a standardized questionnaire) predicted the degree of clinical improvement. The deeper the experience, the greater the healing. And the intensity of the mystical experience correlated with the degree of alpha power reduction and entropy increase on EEG, bringing us back to the core neural mechanism.
The Frontier: EEG Biomarkers for Psychedelic Therapy
One of the most active areas of current research is using EEG to predict and optimize psychedelic therapy outcomes. Several key questions are being pursued.
Can pre-treatment EEG predict who will respond? Preliminary data suggests yes. Baseline frontal alpha asymmetry, default mode network coherence, and overall neural entropy may help identify which patients are most likely to benefit from psychedelic therapy. Patients with the most rigid brain patterns (lowest entropy, highest DMN coherence) may paradoxically be the best candidates, because they have the most to gain from the temporary increase in neural flexibility that psychedelics provide.
Can real-time EEG guide the therapeutic process? Several research groups are exploring the use of EEG during psychedelic sessions to track the depth of the experience and identify critical moments of neural reorganization. The entropy measures, alpha suppression, and DMN coherence changes are all detectable in real time with modern EEG equipment.
Can post-treatment EEG track integration? This might be the most practically valuable application. If we can identify EEG signatures that distinguish successful integration from superficial experiences, clinicians could use follow-up EEG to determine whether a patient needs additional sessions or has achieved the neural reorganization that predicts lasting improvement.
Consumer EEG technology is contributing to this frontier. The Neurosity Crown's 8-channel array (CP3, C3, F5, PO3, PO4, F6, C4, CP4) covers the cortical regions most relevant to psychedelic neuroscience, including frontal prefrontal sites for DMN monitoring and parietal-occipital sites where alpha changes are most pronounced. At 256Hz, it captures the temporal resolution needed for entropy and spectral analysis. While clinical psychedelic therapy requires medical-grade equipment and professional oversight, the Crown's open SDKs and MCP integration make it possible for researchers to build tools that track the neural flexibility and integration patterns that psychedelic therapy is designed to promote.
What the Psychedelic Renaissance Teaches Us About the Brain
Step back from the clinical applications for a moment. The psychedelic renaissance is teaching us something profound about the nature of mental illness itself.
For decades, psychiatry operated on a chemical imbalance model. Depression was a serotonin problem. Anxiety was a GABA problem. ADHD brain patterns was a dopamine problem. Prescribe the right molecule to fix the right imbalance.
That model was always oversimplified, and psychedelic research is exposing just how much. The conditions that psychedelics seem to help most, depression, PTSD, addiction, OCD, share a common feature that has nothing to do with any single neurotransmitter. They're all characterized by rigid patterns of brain activity. Stuck circuits. Neural ruts worn so deep that the brain can't climb out of them through normal processes.
Psychedelics don't fix a chemical imbalance. They temporarily dissolve the patterns themselves. They increase the brain's entropy, its degrees of freedom, its capacity to try something new. And when that happens in the context of skilled therapeutic support, the brain doesn't just return to its old patterns. It reorganizes.
EEG makes this visible. The entropy increase during the experience. The alpha collapse. The DMN dissolution. And afterward, the emergence of new patterns of oscillatory activity that reflect more flexible, less rigidly organized brain states.
This reframe, from chemical imbalance to pattern rigidity, might be the psychedelic renaissance's most lasting contribution to psychiatry. Not the drugs themselves, but what the drugs revealed about how brains get sick and how they can heal.
The most complex object in the known universe can get stuck. It can lock itself into patterns that cause immense suffering. But those patterns aren't permanent. They're maintained by oscillatory dynamics that can be measured, tracked, and changed. We're just beginning to understand how.
And that understanding is worth more than any single molecule.